Neurotensin
Also known as: NT, NTS, neurotensin-13, neuromedin N precursor
Endogenous tridecapeptide neuropeptide (13 amino acids); gut-brain hormone; G protein-coupled receptor (GPCR) ligand; classified as a regulatory neuropeptide an
What it is
Researchers, oncologists, and neuroscientists study neurotensin primarily for its roles in pain relief, psychiatric conditions, cancer imaging, and heart health. Athletes and biohackers have shown interest in its opioid-independent analgesic and appetite-suppressing properties, though no approved human therapeutic currently exists outside investigational settings.
The scientific side
neurotensin (NT) is an endogenous 13-amino acid tridecapeptide that acts through three receptor subtypes: the high-affinity GPCR neurotensin receptor 1 (NTSR1/NTS1), the moderate-affinity GPCR neurotensin receptor 2 (NTSR2/NTS2), and neurotensin receptor 3 (NTSR3/NTS3), structurally identical to sortilin (SORT1). NTSR1 and NTSR2 couple to Gq/Gi G-protein pathways, activating phospholipase C, inositol trisphosphate, and MAP kinase cascades. NTSR2 additionally drives cyclic GMP (cGMP) production, producing antihypertrophic and antifibrotic effects in cardiac lymphatic endothelial cells after ischemic or mechanical injury; selective NTSR2 agonism ameliorates cardiac remodeling and dysfunction in both pressure overload and myocardial infarction models (PMID 42384771). In the central nervous system, NT modulates dopaminergic and monoaminergic circuits. It interacts with dopamine D2 receptors through NTS1-D2 heteroreceptor complexes in the mesolimbic and nigrostriatal pathways, producing antipsychotic-like or propsychotic-like effects depending on the anatomical circuit and whether autoreceptors or postsynaptic populations are engaged (PMID 27141290). This dopaminergic co-modulation underlies NT's relevance to schizophrenia, Parkinson's disease, and substance use pathophysiology. NT also mediates potent opioid-independent antinociception via NTS1 and NTS2 in spinal and supraspinal circuits. NTS1 activation produces strong analgesia but concurrently causes hypothermia and hypotension through peripheral vasodilatory and central thermoregulatory mechanisms, whereas selective NTS2 activation achieves analgesia without these cardiovascular side effects (PMID 36539999, 31589400). Brain-penetrant NT(8-13) analogs conjugated to blood-brain barrier shuttle peptides reverse neuropathic allodynia with minimal adverse effects in rodent models (PMID 42176569). Peripherally, NT acts as an anorexigenic hormone released postprandially and after bariatric surgery, reducing food intake through vagal afferents and direct activation of proopiomelanocortin neurons in the hypothalamic arcuate nucleus (PMID 27580810). NTSR1 is overexpressed in pancreatic, colorectal, prostate, and lung cancers, enabling radiolabeled NT analogs and peptide-drug conjugates for tumor imaging and targeted radiotherapy (PMID 42109681, 42304982). The minimal active binding sequence is NT(8-13); native NT undergoes rapid proteolytic cleavage at Arg8-Arg9, Pro10-Tyr11, and Tyr11-Ile12 bonds, yielding a plasma half-life of approximately 1 to 3 minutes.
Class: Endogenous tridecapeptide neuropeptide (13 amino acids); gut-brain hormone; G protein-coupled receptor (GPCR) ligand; classified as a regulatory neuropeptide and enteroendocrine peptide; investigational non-opioid analgesic scaffold and oncological radioligand vector
Administration & storage
- Administration
- Intravenous (i.v.) — used in most pharmacokineticimagingand CNS analgesic studies in rodentsSubcutaneous (s.c.) — used for NTS1 agonist PD149163 in self-administration and behavioral modelsIntraperitoneal (i.p.) — used for NT analogs in Parkinson's and appetite studies in rodentsIntrathecal (i.t.) — used for spinal antinociception studies with NT(8-13) analogs in ratsIntracerebroventricular (i.c.v.) — used in early rodent central analgesia and thermoregulation studiesIntravenous radiotracer bolus — used in first-in-human PET/CT imaging of prostate cancer (PMID 42304982)
- Storage
- Research-grade lyophilized neurotensin should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are highly unstable and should be used within hours; proteolytic degradation begins rapidly at physiological pH and temperature. Analogs incorporating backbone modifications may have longer reconstituted stability; consult manufacturer specifications for each compound. No pharmaceutical storage standards apply as no approved human formulation exists.
- Cautions
- Native neurotensin and NTS1-active analogs cause marked dose-dependent hypothermia and hypotension via peripheral vasodilation and central thermoregulatory mechanisms; NTS1 activation is the primary driver of these cardiovascular and thermoregulatory adverse effects (PMID 36539999, 31589400),No human safety pharmacology data from controlled trials exist for native neurotensin administered therapeutically; all safety knowledge derives from animal studies and radiotracer imaging contexts,Tolerance to anxiolytic and potentially analgesic effects has been observed with repeated NTS1 agonist administration in rodents, raising concern about tachyphylaxis with chronic use (PMID 24275076),Rapid proteolytic degradation in plasma and tissue limits activity duration but also means any exogenous NT or analogs will generate metabolic breakdown products whose safety profiles in humans are not characterized,NTSR1 overexpression in cancers raises theoretical concern that exogenous NT administration in individuals with undiagnosed malignancies could potentially stimulate tumor proliferation or progression (PMID 42322125),The investigational nature of all neurotensin-based compounds means no validated human dosing, toxicology, or pharmacovigilance data exist outside of clinical trial settings; sourcing from unregulated peptide vendors introduces unknown purity and sterility risks
Legal & regulatory status
Neurotensin itself has no FDA-approved therapeutic indication as of October 2026. No NDA or BLA has been approved for native neurotensin or any unmodified neurotensin analog for human therapeutic use. Radiolabeled…
Neurotensin is not explicitly listed by name on the current WADA Prohibited List. However, neurotensin and its analogs, if used to modulate endogenous pain signaling, suppress appetite, or alter body composition in…
Neurotensin is not approved by Health Canada for any therapeutic indication. Sudocetaxel Zendusortide (TH1902), developed by Theratechnologies (a Canadian company), is a SORT1-directed peptide-drug conjugate with a…
What it's studied for
- Opioid-independent analgesia — acute and neuropathic pain relief via NTS1/NTS2 receptor activation Preclinical / Exploratory (animal models; no human analgesic trials of native NT published)
- Schizophrenia and psychiatric disorders — antipsychotic-like modulation via dopaminergic co-signaling Preclinical and early clinical evidence (animal models + small human observational studies)
- Cancer molecular imaging and targeted radiotherapy — via overexpressed NTSR1 in solid tumors Early clinical / Phase 1 human PET imaging studies (first-in-human data available)
- Cardiac protection — attenuation of adverse cardiac remodeling and heart failure via NTSR2 agonism Preclinical with ex vivo human tissue validation (translational; no published human clinical trial)
- Appetite regulation and obesity — anorexigenic signaling in hypothalamic and gastrointestinal circuits Preclinical / Limited human observational data (bariatric surgery correlative studies)
- Parkinson's disease — neuroprotection of dopaminergic neurons and gene delivery vector Preclinical (animal models of parkinsonism; no published human clinical trials)
- Substance use disorders — reduction of stimulant self-administration and opioid withdrawal modulation Preclinical (animal models; no published human clinical trials)
Safety signals
- Hypothermia — marked body temperature reduction via central and peripheral thermoregulatory mechanisms
- Hypotension — acute blood pressure reduction via peripheral vasodilation mediated by NTS1 activation
- Tachyphylaxis / tolerance to behavioral effects with repeated administration
- Sedation and voluntary movement suppression
- Potential tumor growth promotion via NTSR1 on cancer cells — risk in individuals with undiagnosed malignancy
- Rapid plasma degradation producing bioactive fragments — pharmacokinetic unpredictability with native peptide
- CNS-mediated propsychotic effects — context-dependent actions in dopaminergic circuits
All studies (10)
Frequently asked
Does neurotensin work like an opioid for pain?
Neurotensin produces pain relief through a mechanism that is pharmacologically distinct from opioids — it acts on its own receptor subtypes (NTS1 and NTS2) rather than mu-, delta-, or kappa-opioid receptors. This opioid-independent analgesia is supported by preclinical studies in rodent pain models. However, no neurotensin-based analgesic has completed human clinical trials. Key differences: neurotensin analgesic effects do not appear to cause respiratory depression or constipation (opioid-defining harms) in animal models, but NTS1-active forms can cause significant hypothermia and hypotension. No legitimate human dosing guidance exists.
Can neurotensin help with fat loss or appetite suppression?
Preclinical studies show neurotensin acts as an anorexigenic (appetite-suppressing) peptide in rodents, decreasing food intake through hypothalamic and gut-brain circuits. NT levels also rise after bariatric surgery, suggesting it may contribute to post-surgical appetite reduction. However, native neurotensin degrades within minutes in the bloodstream and no orally available or stable injectable form is approved or validated for human use. No clinical trials of neurotensin for obesity or body weight management have been completed.
Is neurotensin legal to buy and use?
Neurotensin is not an approved drug in the US, Canada, or most jurisdictions, meaning it cannot legally be sold, marketed, or prescribed for human therapeutic use. Research-grade neurotensin peptide is available from chemical suppliers for laboratory use only. For athletes, neurotensin is not named on the WADA Prohibited List but could be captured under the non-approved substances category (S0) if used for performance-enhancing purposes. Purchasing research peptides for self-administration exists in a legal grey area; the purity, sterility, and safety of such products cannot be guaranteed.
What is the difference between NTS1 and NTS2 receptor activation?
Neurotensin has two main G protein-coupled receptor targets with different tissue distributions and effect profiles. NTS1 (high-affinity) is expressed broadly in brain, gut, and peripheral tissues and mediates most of NT's central effects including analgesia, dopamine modulation, and cardiovascular/thermoregulatory changes — including the problematic hypothermia and hypotension. NTS2 (moderate-affinity) is primarily brain-expressed and when selectively activated produces analgesia without the cardiovascular side effects. This receptor subtype selectivity is a major focus of current NT analog drug development research.
Has neurotensin been tested in humans?
Human data for neurotensin is largely limited to diagnostic imaging contexts. A first-in-human PET imaging study of a radiolabeled NT analog ([18F]-AlF-NOTA-neurotensin) was conducted in 23 prostate cancer patients, primarily as a diagnostic tracer and not as a treatment (PMID 42304982). A neurotensin receptor 3-targeting peptide-drug conjugate (Sudocetaxel Zendusortide / TH1902) has completed Phase 1 evaluation in solid tumor patients (PMID 42425329). No clinical trials of neurotensin for pain, psychiatry, obesity, or any consumer wellness indication have been published.